Last reviewed · How we verify
NCT05675787
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Phase 2 trial testing Medroxyprogesterone acetate + Atorvastatin in Atypical Endometrial Hyperplasia in 82 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 6 January 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Medroxyprogesterone acetate + Atorvastatin — full drug profile →
Conditions studied
- Atypical Endometrial Hyperplasia — all drugs for Atypical Endometrial Hyperplasia →
- Endometrial Carcinoma Stage I — all drugs for Endometrial Carcinoma Stage I →
Sponsor
Peking University People's Hospital
Who can join
Adults 17 to 45, female only, with Atypical Endometrial Hyperplasia or Endometrial Carcinoma Stage I. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications.
Wang X, Li Y, Hou X, Li J, et al · · 2024 · cited 22× · PMID 39256811 · DOI 10.1186/s12964-024-01792-7
Verify or expand the search:
- PubMed search for NCT05675787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atypical Endometrial Hyperplasia
Currently open trials in the same condition.
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT05316935 — GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients · Phase 2, PHASE3 · recruiting
- NCT06379113 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients · Phase 2, PHASE3 · recruiting
- NCT06390904 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients · Phase 2, PHASE3 · active not recruiting
- NCT05316493 — Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia · Phase 2, PHASE3 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05675787 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 11 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing